PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Pharmacological PP2A activation is a druggable approach to overcome MEK inhibitor resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, in two cancer drug response screens, CIP2A depletion was shown to increase the therapeutic response of HeLa and KRAS-mutant lung cancer cells to various cancer therapies (12,13).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [13]
In the citing paper
“The results also support the earlier findings that CIP2A-deficient tumors could constitute a more therapy sensitive subtype (10,12,13).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [13]
In the citing paper
“A series of small molecule PP2A activators, previously termed SMAPs and engineered from phenothiazine parent compounds, drive dephosphorylation of select pathogenic substrates such as c-MYC and ERK with concordant tumor inhibition in an array of in vivo cancer models (Allen-Petersen et al., 2018; Kauko et al., 2018; Sangodkar et al., 2017b).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Kauko et al., 2018
In the citing paper
“In line with the inability to stabilize AB56αC heterotrimers, these derivative compounds did not induce apoptosis in standard cell culture conditions and had a significantly reduced effect in low serum culture conditions as determined by GI50s (Fig. 4C; Fig S4A) (Kauko et al., 2018; McClinch et al., 2018; Sangodkar et al., 2017a; Tohmé et al., 2019).”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Kauko et al., 2018
In the citing paper
“Importantly, phosphatase activation alone was inferior to the kinase inhibitor treatment alone.”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Kauko et al., 2018
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159 · cited 4×
“Whereas PPP2R1A depletion models cells with persistent PP2A inhibition (12), depletion of PP2A inhibitors CIP2A and PME-1 results in cells with tonally high PP2A activity (15, 20).”
InfluentialRetractedControlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Rectangular Confidence Regions for the Means of Multivariate Normal Distributions
Šidák, Z. (1967) · Journal of the American Statistical Association · doi:10.1080/01621459.1967.10482935 · Cited by 2,639 · cited 1×
“When performing multiple comparisons, alpha level was adjusted by Šidák’s (47) or Dunnett’s correction, or FDR was controlled by the BenjaminiHochberg procedure (48).”
MethodRectangular Confidence Regions for the Means of Multivariate Normal Distributions
Šidák, Z. (1967) · Journal of the American Statistical Association · doi:10.2307/2283989 · Cited by 1,455
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Self-citationEnumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., DeCaprio, J. A., & Weinberg, R. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.7.2111-2123.2002 · Cited by 612
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins
Ramirez, R. D., Sheridan, S., Girard, L., Sato, M., Kim, Y., Pollack, J., Peyton, M., Zou, Y., Kurie, J. M., DiMaio, J. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3703 · Cited by 607
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585 · cited 1×
“The qualitative difference between cytostatic and cytotoxic response is thought to be important with regard to potential development of therapy resistance and regrowth of the tumor (44).”
BackgroundSpecies- and cell type-specific requirements for cellular transformation
Rangarajan, A., Hong, S. J., Gifford, A., & Weinberg, R. A. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.07.009 · Cited by 555 · cited 2×
“In full accordance with a requirement of PP2A inhibition for cellular transformation by activated RAS (6, 7), PP2A inhibition promotes malignant growth of various cell types with RAS activating mutations (15, 17).”
Background
Cited by
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 226
Serine, glycine and one‑carbon metabolism in cancer (Review)
Pan, S., Fan, M., Liu, Z., Li, X., & Wang, H. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5158 · Cited by 227
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer
Vervoort, S. J., Welsh, S. A., Devlin, J. R., Barbieri, E., Knight, D. A., Offley, S., Bjelosevic, S., Costacurta, M., Todorovski, I., Kearney, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.022 · Cited by 219
Self-citation
Metadata
- Authors
- Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., Haapaniemi, P., Momeny, M., Varila, T., Ohlmeyer, M., Aittokallio, T., Wennerberg, K., Narla, G., & Westermarck, J.
- Affiliations
- Åbo Akademi University (FI)
- Case Comprehensive Cancer Center (US)
- University of Helsinki (FI)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- O’Connor, Caitlin M.
- Kulesskiy, Evgeny
- Narla, Goutham
- Westermarck, Jukka
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC8335581
- OpenAlex
- W2884137656
- Semantic Scholar
- 7b4b368bc66efb46734e7ae6188a052e7a61d290
- Cited by
- 149
- References
- 48
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 14 · 2023: 21 · 2022: 22 · 2021: 24 · 2020: 19 · 2019: 20 · 2018: 5
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- NIH Office of the Director (R01 CA181654)
- Sigrid Juséliuksen Säätiö
- Academy of Finland (252572, 294850, 310507, 277293)
- Cancer Society of Finland
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- protein phosphatase 2A, PP2A inhibition, MEK inhibitor resistance, KRAS-mutant lung cancer, Akt/mTOR signaling, selumetinib, kinase inhibitor resistance, serine/threonine phosphatase, combination therapy
- MeSH terms
- Animals, Humans, Lung Neoplasms, Male, Mice, Inbred BALB C, Mice, Nude, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), Cellular Senescence, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Protein Phosphatase 2, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. https://app.cochat.ai/papers/10.1126/scitranslmed.aaq1093
- The paper
- Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., Haapaniemi, P., Momeny, M., Varila, T., Ohlmeyer, M., Aittokallio, T., Wennerberg, K., Narla, G., & Westermarck, J. (2018). PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaq1093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.